Insights

Innovative Therapeutics Obsidian Therapeutics specializes in controllable cell and gene therapies utilizing their proprietary cytoDriveTM technology, which enhances therapeutic efficacy, presenting opportunities to partner on advanced personalized medicine solutions.

Strong Funding Backing With over 160 million dollars secured in Series C financing from prominent investors like Wellington Management, there is substantial financial capacity to expand R&D collaborations and clinical trial services.

Recent Industry Engagements Obsidian actively participates in major industry conferences such as AACR, ASCO, and JPM Healthcare, indicating openness to strategic partnerships, licensing deals, and collaborative research opportunities.

Leadership & Talent Recent hires of senior executives including a Chief Technology Officer and key board members from notable investment firms signal a focus on technological advancement and strategic growth, suggesting potential for engaging with their leadership for joint initiatives.

Market Position & Potential Operating in a competitive biotech landscape with a revenue range of 50 to 100 million dollars and a growing pipeline positions Obsidian as a promising partner for innovative therapeutics, particularly in the cell and gene therapy space aimed at intractable diseases.

Obsidian Therapeutics Tech Stack

Obsidian Therapeutics uses 8 technology products and services including CIM Technologies, Open Graph, SAP, and more. Explore Obsidian Therapeutics's tech stack below.

  • CIM Technologies
    Cad & Graphics
  • Open Graph
    Content Management System
  • SAP
    Customer Relationship Management
  • MySQL
    Database
  • Microsoft PowerPoint
    Editors
  • Font Awesome
    Font Scripts
  • Microsoft Project
    Project Management
  • Google Tag Manager
    Tag Management

Media & News

Obsidian Therapeutics's Email Address Formats

Obsidian Therapeutics uses at least 1 format(s):
Obsidian Therapeutics Email FormatsExamplePercentage
FLast@obsidiantx.comJDoe@obsidiantx.com
89%
First.Last@obsidiantx.comJohn.Doe@obsidiantx.com
5%
LastFirst@obsidiantx.comDoeJohn@obsidiantx.com
4%
First_Last@obsidiantx.comJohn_Doe@obsidiantx.com
2%

Frequently Asked Questions

Where is Obsidian Therapeutics's headquarters located?

Minus sign iconPlus sign icon
Obsidian Therapeutics's main headquarters is located at 1030 Massachusetts Avenue, Suite 400 Cambridge, MA 02138, US. The company has employees across 2 continents, including North AmericaEurope.

What is Obsidian Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Obsidian Therapeutics's official website is obsidiantx.com and has social profiles on LinkedInCrunchbase.

What is Obsidian Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign icon
Obsidian Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Obsidian Therapeutics have currently?

Minus sign iconPlus sign icon
As of October 2025, Obsidian Therapeutics has approximately 86 employees across 2 continents, including North AmericaEurope. Key team members include Chief Executive Officer: M. J.Chief Development Officer (cdo): P. H.Chief Financial And Operating Officer: J. T.. Explore Obsidian Therapeutics's employee directory with LeadIQ.

What industry does Obsidian Therapeutics belong to?

Minus sign iconPlus sign icon
Obsidian Therapeutics operates in the Biotechnology Research industry.

What technology does Obsidian Therapeutics use?

Minus sign iconPlus sign icon
Obsidian Therapeutics's tech stack includes CIM TechnologiesOpen GraphSAPMySQLMicrosoft PowerPointFont AwesomeMicrosoft ProjectGoogle Tag Manager.

What is Obsidian Therapeutics's email format?

Minus sign iconPlus sign icon
Obsidian Therapeutics's email format typically follows the pattern of FLast@obsidiantx.com. Find more Obsidian Therapeutics email formats with LeadIQ.

How much funding has Obsidian Therapeutics raised to date?

Minus sign iconPlus sign icon
As of October 2025, Obsidian Therapeutics has raised $115M in funding. The last funding round occurred on Sep 09, 2021 for $115M.

When was Obsidian Therapeutics founded?

Minus sign iconPlus sign icon
Obsidian Therapeutics was founded in 2015.
Obsidian Therapeutics

Obsidian Therapeutics

Biotechnology ResearchUnited States51-200 Employees

Obsidian Therapeutics is pioneering controllable cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian’s programs apply our cytoDriveTM technology in cell and gene therapy products to control expression of proteins for enhanced therapeutic efficacy, including our lead program cytoTIL15 engineered to make TILs more effective for more patients.
 
Our aspirations are high, and we’re built to deliver – well-funded with blue chip investors, engaged field-leading advisors, strong partnerships with industry leaders, and a highly experienced, dynamic, innovative and collaborative team, collectively focused on delivering transformative therapies in areas of greatest clinical need.

Located in the heart of Cambridge with a new laboratory facility in Bedford, we’re proud of our diverse talented team and committed to cultivating an environment of inclusion where we strive to instill a strong sense of belonging, and support each Obsidianite to continuously learn and contribute their best work.  We offer competitive salary and benefits, and potential for employee ownership through stock options.

Section iconCompany Overview

Headquarters
1030 Massachusetts Avenue, Suite 400 Cambridge, MA 02138, US
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2015
Employees
51-200

Section iconFunding & Financials

  • $115M

    Obsidian Therapeutics has raised a total of $115M of funding over 1 rounds. Their latest funding round was raised on Sep 09, 2021 in the amount of $115Mas a Series B.

  • $50M$100M

    Obsidian Therapeutics's revenue is estimated to be in the range of $50M$100M

Section iconFunding & Financials

  • $115M

    Obsidian Therapeutics has raised a total of $115M of funding over 1 rounds. Their latest funding round was raised on Sep 09, 2021 in the amount of $115Mas a Series B.

  • $50M$100M

    Obsidian Therapeutics's revenue is estimated to be in the range of $50M$100M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.